Tarceva, Kepivance, And Macugen Approvals Are Quiet Milestones For FDA
Executive Summary
Genentech/OSI's Tarceva, Amgen's Kepivance and Pfizer/Eyetech's Macugen are the first three products approved under the "continuous marketing application" pilot program
You may also be interested in...
Macugen Access Program Will Help Seniors With Medicare Copay
The Macugen Access Program will help seniors cover the 20% Medicare copay, Eyetech COO Paul Chaney said
Macugen Access Program Will Help Seniors With Medicare Copay
The Macugen Access Program will help seniors cover the 20% Medicare copay, Eyetech COO Paul Chaney said
Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B